<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04457245</url>
  </required_header>
  <id_info>
    <org_study_id>20-000378</org_study_id>
    <secondary_id>NCI-2020-03445</secondary_id>
    <secondary_id>20-000378</secondary_id>
    <nct_id>NCT04457245</nct_id>
  </id_info>
  <brief_title>Randomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer</brief_title>
  <acronym>PSMA-dRT</acronym>
  <official_title>Phase 3 Randomized Trial Of PSMA PET Prior to Definitive Radiation Therapy for Unfavorable Intermediate-Risk or High-Risk Prostate Cancer [PSMA dRT]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Progenics Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase III trial studies the success rate of definitive radiation therapy
      (dRT) for prostate cancer (PCa) with or without planning based on PSMA PET. PSMA- PET-based
      dRT, may improve radiation therapy planning and patient selection for dRT, and potentially
      improve its outcome compared to dRT without PSMA PET (standard dRT).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:

      I. To compare the outcome of patients with unfavorable intermediate (IR) and high-risk (HR)
      prostate cancer (PCa) after standard dRT versus prostate-specific membrane antigen (PSMA)
      positron emission tomography (PET)-based dRT.

      OUTLINE: Patients are randomized to 1 of 2 arms. In both arms, no other primary treatment
      should be given before RT.

      Arm I: Patients do not undergo PSMA PET for dRT planning. Patients undergo standard of care
      dRT at the discretion of the treating radiation oncologist.

      Arm II: Patients undergo PSMA PET for dRT planning. Patients then undergo dRT at the
      discretion of the treating radiation oncologist, who receives the PSMA PET result and images.

      After completion of dRT, clinical follow-up of patients with their treating radiation
      oncologist will be obtained for 5 years. The investigators will rely on the medical records
      obtained from the treating physicians as the primary source of outcome data.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2027</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Success rate of definitive radiation therapy (dRT)</measure>
    <time_frame>From date of randomization to first occurrence of progression, assessed up to 5 years</time_frame>
    <description>Will be measured as progression-free survival after initiation of dRT. Progression is defined as (whichever occurs first): A biochemical recurrence defined as a rise by 2 ng/mL or more above the nadir prostate specific antigen (PSA) (defined as the lowest PSA achieved) after radiotherapy with or without short-term hormonal therapy, appearance of metastasis or loco-regional recurrence (diagnosed by any imaging or biopsy), initiation of any new salvage therapy or death from any cause. Survival curves will be constructed using the Kaplan-Meier method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Loco-regional progression free survival</measure>
    <time_frame>Up to 5 years after the date of randomization</time_frame>
    <description>Diagnosis of local recurrence or pelvic nodal disease (N1) can be obtained by any imaging or biopsy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metastasis-free survival after initiation of radiation therapy (RT)</measure>
    <time_frame>Up to 5 years after the date of randomization</time_frame>
    <description>Diagnosis of extra-pelvic metastatic (M1) disease can be obtained by any imaging or biopsy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 5 years after the date of randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in initial treatment intent</measure>
    <time_frame>Baseline up to 5 years after the date of randomization</time_frame>
    <description>Will estimate the proportion of subjects in the prostate-specific membrane antigen (PSMA) group that have a change in the initial treatment intent and compute a 95% confidence interval for that proportion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSMA positron emission tomography (PET) derived predictors of progression-free survival</measure>
    <time_frame>Up to 5 years after the date of randomization</time_frame>
    <description>Will use Cox-proportional hazards regression to assess PSMA PET predictors of progression-free survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSMA PET derived predictors of overall survival</measure>
    <time_frame>Up to 5 years after the date of randomization</time_frame>
    <description>Will use Cox-proportional hazards regression to assess PSMA PET predictors of overall survival.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">312</enrollment>
  <condition>Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8</condition>
  <condition>Stage II Prostate Cancer AJCC v8</condition>
  <condition>Stage IIA Prostate Cancer AJCC v8</condition>
  <condition>Stage IIB Prostate Cancer AJCC v8</condition>
  <condition>Stage IIC Prostate Cancer AJCC v8</condition>
  <condition>Stage III Prostate Cancer AJCC v8</condition>
  <condition>Stage IIIA Prostate Cancer AJCC v8</condition>
  <condition>Stage IIIB Prostate Cancer AJCC v8</condition>
  <condition>Stage IIIC Prostate Cancer AJCC v8</condition>
  <arm_group>
    <arm_group_label>Arm I (dRT)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>150 Patients undergo standard dRT at the discretion of the treating radiation oncologist. Patient does not undergo PSMA PET for RT planning. Any other imaging is allowed, including CT/BS/MR/PET depending on local practice. No other primary treatment can be given before dRT. If a patient assigned to the control arm undergo a PSMA PET scan at another institution he will be discontinued from the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (18F-DCFPyL, PET/CT, dRT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>162 Patient undergoes PSMA PET with 18F-DCFPyL for dRT planning. Any other imaging is allowed, including CT/BS/MR/PET depending on local practice. Patients then undergo dRT at the discretion of the treating radiation oncologist, who receives PSMA PET results and images. No other primary treatment can be given before RT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Computed Tomography</intervention_name>
    <description>Undergo whole body PET/CT</description>
    <arm_group_label>Arm II (18F-DCFPyL, PET/CT, dRT)</arm_group_label>
    <other_name>CAT</other_name>
    <other_name>CAT Scan</other_name>
    <other_name>Computerized Axial Tomography</other_name>
    <other_name>Computerized Tomography</other_name>
    <other_name>CT</other_name>
    <other_name>CT Scan</other_name>
    <other_name>tomography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fluorine F 18 DCFPyL</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm II (18F-DCFPyL, PET/CT, dRT)</arm_group_label>
    <other_name>18F-DCFPyL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Undergo whole body PET/CT</description>
    <arm_group_label>Arm II (18F-DCFPyL, PET/CT, dRT)</arm_group_label>
    <other_name>Medical Imaging, Positron Emission Tomography</other_name>
    <other_name>PET</other_name>
    <other_name>PET Scan</other_name>
    <other_name>Positron Emission Tomography Scan</other_name>
    <other_name>Positron-Emission Tomography</other_name>
    <other_name>proton magnetic resonance spectroscopic imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <description>Undergo standard of care definitive radiation therapy</description>
    <arm_group_label>Arm I (dRT)</arm_group_label>
    <arm_group_label>Arm II (18F-DCFPyL, PET/CT, dRT)</arm_group_label>
    <other_name>Cancer Radiotherapy</other_name>
    <other_name>Irradiate</other_name>
    <other_name>Irradiated</other_name>
    <other_name>Irradiation</other_name>
    <other_name>Radiation</other_name>
    <other_name>Radiation Therapy, NOS</other_name>
    <other_name>Radiotherapeutics</other_name>
    <other_name>Radiotherapy</other_name>
    <other_name>RT</other_name>
    <other_name>Therapy, Radiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult male 18 years or older

          -  Histopathologically-proven PCa

          -  Unfavorable IR to HR disease:

               -  Prostate specific antigen (PSA) &gt;= 10 ng/mL

               -  Or cT-stage &gt;= 2b

               -  Or Gleason grade 3 (4+3=7) or higher

               -  Or Gleason grade 2 (3+4=7) AND &gt;= 50% positive biopsy cores

               -  Or Decipher Score &gt;= 0.45

          -  Treating radiation oncologist intends to incorporate PSMA PET findings into the
             radiotherapy plan, if patient undergoes PSMA PET (intervention arm 2)

          -  Provision of signed and dated informed consent form

          -  Stated willingness to comply with all study procedures and availability for the
             duration of the study

        Exclusion Criteria:

          -  Less than 18 years old at the time of investigational product administration

          -  Extra-pelvic metastasis (M1 disease) on any imaging or biopsy done before
             randomization

          -  Prior PSMA PET

          -  Prior pelvic RT

          -  Contraindications to radiotherapy (including active inflammatory bowel disease)

          -  Concurrent or prior surgery or systemic therapy for PCa at the time of randomization
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeremie Calais</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCLA / Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA / Jonsson Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Jeremie Calais</last_name>
      <phone>310-825-3617</phone>
      <email>jcalais@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Jeremie Calais</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 30, 2020</study_first_submitted>
  <study_first_submitted_qc>June 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2020</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PSMA</keyword>
  <keyword>PET/CT</keyword>
  <keyword>randomized trial</keyword>
  <keyword>definitive Radiation Therapy</keyword>
  <keyword>prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorides</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

